Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex

Cancer Discovery

Volumn 7, Issue 3, 2017, Pages 302-321

  Zawistowski, Jon S ^a   Bevill, Samantha M ^a   Goulet, Daniel R ^a   Stuhlmiller, Timothy J ^a   Beltran, Adriana S ^a   Olivares Quintero, Jose F ^a   Singh, Darshan ^a   Sciaky, Noah ^a   Parker, Joel S ^a   Rashid, Naim U ^b   Chen, Xin ^a   Duncan, James S ^a   Whittle, Martin C ^a   Angus, Steven P ^a   Velarde, Sara Hanna ^a   Golitz, Brian T ^a   He, Xiaping ^a   Santos, Charlene ^a   Darr, David B ^a   Gallagher, Kristalyn ^a   Graves, Lee M ^a   Perou, Charles M ^a   Carey, Lisa A ^a   Shelton Earp, H ^a   Johnson, Gary L ^a   more..

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 7 (3,5 DIMETHYL 4 ISOXAZOLYL) 1,3 DIHYDRO 8 METHOXY 1 [1 (2 PYRIDINYL)ETHYL] 2H IMIDAZO[4,5 C]QUINOLIN 2 ONE; B RAF KINASE INHIBITOR; BORTEZOMIB; BROMODOMAIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TRAMETINIB; (+)-JQ1 COMPOUND; ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; BRD4 PROTEIN, HUMAN; DDR1 PROTEIN, HUMAN; DISCOIDIN DOMAIN RECEPTOR 1; FUSED HETEROCYCLIC RINGS; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; NUCLEAR PROTEIN; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST BIOPSY; CANCER STAGING; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; FEMALE; GENE DELETION; GENE EXPRESSION; GENE LIBRARY; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RNA SEQUENCE; TRANSCRIPTION REGULATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; WESTERN BLOTTING; WHOLE EXOME SEQUENCING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CLINICAL TRIAL; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; ENHANCER REGION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZEPINES; CELL LINE, TUMOR; DISCOIDIN DOMAIN RECEPTOR 1; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; FEMALE; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE, INBRED BALB C; MICE, SCID; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B; PYRIDONES; PYRIMIDINONES; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TRIAZOLES; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85014769818     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0653     Document Type: Article

References (55)

1. Zhou B, Der CJ, Cox AD. The role of wild type RAS isoforms in cancer. Semin Cell Dev Biol 2016; 58: 60-9.
2. Genomic Data Commons Data Portal. Available from: https://gcd-portal. nci.nih.gov
3. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat J-P, et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251-63.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
5. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-7.
6. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-62.
7. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol Off J Am Soc Clin Oncol 2011; 29: 2046-51.
8. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
9. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012; 149: 307-21.
10. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
11. Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol 2016; 8: 48-56.
12. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013; 14: 249-56.
13. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-88.
14. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18: 683-95.
15. Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen H-Y, et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep 2013; 4: 1090-9.
16. Tricker EM, Xu C, Uddin S, Capelletti M, Ercan D, Ogino A, et al. Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov 2015; 5: 960-71.
17. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007; 26: 3909-19.
18. Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell 1999; 3: 169-79.
19. Jaenicke LA, von Eyss B, Carstensen A, Wolf E, Xu W, Greifenberg AK, et al. Ubiquitin-dependent turnover of MYC antagonizes MYC/PAF1C complex accumulation to drive transcriptional elongation. Mol Cell 2016; 61: 54-67.
20. Kuras L, Borggrefe T, Kornberg RD. Association of the mediator complex with enhancers of active genes. Proc Natl Acad Sci U S A 2003; 100: 13887-91.
21. Petrenko N, Jin Y, Wong KH, Struhl K. Mediator undergoes a compositional change during transcriptional activation. Mol Cell 2016; 64: 443-54.
22. Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A 2010; 107: 21931-6.
23. Ostuni R, Piccolo V, Barozzi I, Polletti S, Termanini A, Bonifacio S, et al. Latent enhancers activated by stimulation in differentiated cells. Cell 2013; 152: 157-71.
24. Kaikkonen MU, Spann NJ, Heinz S, Romanoski CE, Allison KA, Stender JD, et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol Cell 2013; 51: 310-25.
25. Brown JD, Lin CY, Duan Q, Griffin G, Federation AJ, Paranal RM, et al. NF-κB directs dynamic super enhancer formation in infl ammation and atherogenesis. Mol Cell 2014; 56: 219-31.
26. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011; 43: 27-33.
27. Nabet B, Ó Broin P, Reyes JM, Shieh K, Lin CY, Will CM, et al. Deregulation of the Ras-Erk signaling axis modulates the enhancer landscape. Cell Rep 2015; 12: 1300-13.
28. Webster DE, Barajas B, Bussat RT, Yan KJ, Neela PH, Flockhart RJ, et al. Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition. Genome Res 2014; 24: 751-60.
29. Li B, Dewey CN. RSEM: accurate transcript quantification from RNASeq data with or without a reference genome. BMC Bioinformatics 2011; 12: 323.
30. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 2015; 163: 506-19.
31. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8: R76.
32. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A 2012; 109: 2778-83.
33. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.
34. Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep 2015; 11: 390-404.
35. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545-50.
36. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-73.
37. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrinetherapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013; 4: 1116-30.
38. Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, et al. Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res Off J Am Assoc Cancer Res 2013; 19: 4889-99.
39. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 2000; 19: 1020-7.
40. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011; 146: 633-44.
41. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res BCR 2010; 12: R68.
42. Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedic M, et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 2011; 8: 149-63.
43. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-73.
44. Machanick P, Bailey TL. MEME-ChIP: motif analysis of large DNA datasets. Bioinforma Oxf Engl 2011; 27: 1696-7.
45. Parker SCJ, Stitzel ML, T aylor D L, O rozco J M, E rdos M R, A kiyama JA, et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc Natl Acad Sci U S A 2013; 110: 17921-6.
46. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013; 153: 320-34.
47. Pfefferle AD, Agrawal YN, Koboldt DC, Kanchi KL, Herschkowitz JI, Mardis ER, et al. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers. Dis Model Mech 2016; 9: 749-57.
48. Rahman S, Sowa ME, Ottinger M, Smith JA, Shi Y, Harper JW, et al. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol 2011; 31: 2641-52.
49. Liu W, Ma Q, Wong K, Li W, Ohgi K, Zhang J, et al. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell 2013; 155: 1581-95.
50. Devaiah BN, Singer DS. Cross-talk among RNA polymerase II kinases modulates C-terminal domain phosphorylation. J Biol Chem 2012; 287: 38755-66.
51. Hay DA, Fedorov O, Martin S, Singleton DC, Tallant C, Wells C, et al. Discovery and optimization of small-molecule ligands for the CBP/ p300 bromodomains. J Am Chem Soc 2014; 136: 9308-19.
52. Wang L, Chang J, Varghese D, Dellinger M, Kumar S, Best AM, et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun 2013; 4: 2035.
53. Itzen F, Greifenberg AK, Bösken CA, Geyer M. Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. Nucleic Acids Res 2014; 42: 7577-90.
54. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol Off J Am Soc Clin Oncol 2009; 27: 1160-755. https://github.com/darshansinghunc/chippeakanalysis
55. Heiman M, Kulicke R, Fenster RJ, Greengard P, Heintz N. Cell typespecific mRNA purification by translating ribosome affinity purification (TRAP). Nat Protoc 2014; 9: 1282-91.